Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
1. Mineralys closed a public offering of 11.27 million shares at $25.50 each. 2. Gross proceeds from the offering were approximately $287.5 million. 3. Funds will support clinical development and commercialization of lorundrostat. 4. Major underwriters included BofA Securities and Goldman Sachs. 5. Mineralys focuses on hypertension and comorbidities like CKD and OSA.